TrovaGene Inc (NASDAQ:TROV), which happens to be a top end precision medicine biotechnology provider has proceeded to make the much awaited announcement. Through one of its top officials, it revealed that it was going to collaborate with a worldwide, premier biopharmaceutical company, an agreement that would see the two engage in the provision of Trovera® urine circulating tumor DNA (ctDNA) biomarker tests and services.
According to Yahoo, Trovera® urine and blood liquid biopsy tests will be found quite useful by the researchers in carrying out various assessments as well as in doing a proper monitoring of the mutation status in clinical trials.
The Chief Executive Officer of Trovagene, Bill Welch in a recent board meeting said, “We’re pleased to have our liquid biopsy tests included in the clinical trials with a leading biopharmaceutical company and to participate in their development of transformative therapies to improve the lives of cancer patients worldwide. This agreement follows a separate, recent announcement of our collaboration with AstraZeneca and demonstrates the value of our Trovera® biomarker technology.”
Trovagene has over the years performed well in business despite the numerous challenges it has had to struggle with. A number of the top biopharmaceutical companies and clinical research third parties have a lot to thank the provider for. It has over the years performed a wide range of the CLIA laboratory testing services which have benefited the above mentioned bodies immensely.
These are not the first two providers to come together under a common course. A lot of the top trusted providers do not rise to the top to become industry leaders on their own. They collaborate with each other to reach their set goals.
Technological advancement has been given a lot of credit by some top researchers and experts. They have helped push towards the development of top solutions that have helped a lot of patients globally. The top provider is looking forward to generating higher revenues in future. It intends to use them to implement major business expansions.